Aliskiren-induced QT interval prolongation

Gregory J. Peitz, Mark A. Malesker, S. George Sojka

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aliskiren gained FDA approval for the treatment of hypertension in 2007. It is the first approved pharmaceutical to manage hypertension by direct renin inhibition. With the introduction of novel drugs and mechanisms of action comes the challenge of monitoring for new unreported adverse events. The side effect profile for aliskiren has not yet been fully described. We describe the first apparent report of aliskiren-induced QT prolongation resulting in torsades de pointes.

Original languageEnglish
Pages (from-to)411-412
Number of pages2
JournalSouthern Medical Journal
Volume102
Issue number4
DOIs
StatePublished - Apr 2009

Fingerprint

Hypertension
Torsades de Pointes
Renin
Pharmaceutical Preparations
aliskiren

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Aliskiren-induced QT interval prolongation. / Peitz, Gregory J.; Malesker, Mark A.; Sojka, S. George.

In: Southern Medical Journal, Vol. 102, No. 4, 04.2009, p. 411-412.

Research output: Contribution to journalArticle

Peitz, Gregory J. ; Malesker, Mark A. ; Sojka, S. George. / Aliskiren-induced QT interval prolongation. In: Southern Medical Journal. 2009 ; Vol. 102, No. 4. pp. 411-412.
@article{60c21d2eb7454f04b5cb83bd0eb4431c,
title = "Aliskiren-induced QT interval prolongation",
abstract = "Aliskiren gained FDA approval for the treatment of hypertension in 2007. It is the first approved pharmaceutical to manage hypertension by direct renin inhibition. With the introduction of novel drugs and mechanisms of action comes the challenge of monitoring for new unreported adverse events. The side effect profile for aliskiren has not yet been fully described. We describe the first apparent report of aliskiren-induced QT prolongation resulting in torsades de pointes.",
author = "Peitz, {Gregory J.} and Malesker, {Mark A.} and Sojka, {S. George}",
year = "2009",
month = "4",
doi = "10.1097/SMJ.0b013e31818fc03a",
language = "English",
volume = "102",
pages = "411--412",
journal = "Southern Medical Journal",
issn = "0038-4348",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Aliskiren-induced QT interval prolongation

AU - Peitz, Gregory J.

AU - Malesker, Mark A.

AU - Sojka, S. George

PY - 2009/4

Y1 - 2009/4

N2 - Aliskiren gained FDA approval for the treatment of hypertension in 2007. It is the first approved pharmaceutical to manage hypertension by direct renin inhibition. With the introduction of novel drugs and mechanisms of action comes the challenge of monitoring for new unreported adverse events. The side effect profile for aliskiren has not yet been fully described. We describe the first apparent report of aliskiren-induced QT prolongation resulting in torsades de pointes.

AB - Aliskiren gained FDA approval for the treatment of hypertension in 2007. It is the first approved pharmaceutical to manage hypertension by direct renin inhibition. With the introduction of novel drugs and mechanisms of action comes the challenge of monitoring for new unreported adverse events. The side effect profile for aliskiren has not yet been fully described. We describe the first apparent report of aliskiren-induced QT prolongation resulting in torsades de pointes.

UR - http://www.scopus.com/inward/record.url?scp=67651171386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651171386&partnerID=8YFLogxK

U2 - 10.1097/SMJ.0b013e31818fc03a

DO - 10.1097/SMJ.0b013e31818fc03a

M3 - Article

VL - 102

SP - 411

EP - 412

JO - Southern Medical Journal

JF - Southern Medical Journal

SN - 0038-4348

IS - 4

ER -